Welcome to our dedicated page for JOHNSON & JOHNSON SEC filings (Ticker: JNJ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Johnson & Johnson filings document the regulatory record for a New Jersey healthcare company with Innovative Medicine and MedTech operations. Recent 8-K reports cover sales and earnings releases, dividend actions, annual meeting voting results and other material corporate events.
The company’s proxy materials describe board elections, executive compensation votes and shareholder governance matters. Its exchange-registered securities include JNJ common stock and multiple NYSE-listed notes with maturities extending across the company’s long-term debt profile.
Johnson & Johnson CEO and Chairman Joaquin Duato reported receiving an equity award tied to company performance. On February 9, 2026, he acquired 73,054 Performance Share Units (PSUs) at a price of $0 per unit. These PSUs were originally granted on February 13, 2023 under the long-term incentive plan and convert into an equal number of Johnson & Johnson common shares upon vesting, based on performance conditions that were certified on February 9, 2026.
Johnson & Johnson executive equity award: Vice President and Corporate Controller Robert J. Decker acquired 2,741 Performance Share Units (PSUs) on February 9, 2026 as a grant under the company’s long-term incentive plan. These PSUs were originally granted on February 13, 2023 and convert into shares of common stock upon vesting, with the final number reflecting certified achievement of performance conditions.
Johnson & Johnson executive Kathryn E. Wengel reported an equity award tied to company performance. On February 9, 2026, she acquired 13,706 Performance Share Units at a price of $0 under Johnson & Johnson’s long-term incentive plan.
The PSUs were originally granted on February 13, 2023 and convert into shares of common stock when they vest. The 13,706 units represent the target grant amount adjusted based on achievement of the performance conditions specified in the award agreement, as certified on February 9, 2026. Following this transaction, she directly holds 13,706 derivative securities in the form of PSUs.
Johnson & Johnson executive Vanessa Broadhurst, EVP, Global Corporate Affairs, reported an equity compensation transaction. On February 9, 2026, she acquired 8,594 Performance Share Units (PSUs) at a price of $0 per unit under the company’s long-term incentive plan.
The PSUs were originally granted on February 13, 2023 and convert into shares of Johnson & Johnson common stock upon vesting. The reported 8,594-unit figure reflects the target PSUs adjusted based on achievement of performance conditions, which were certified on February 9, 2026. Following this transaction, she directly holds 8,594 derivative securities linked to common stock.
Johnson & Johnson has filed a shelf registration that allows it to offer debt securities from time to time after the registration becomes effective. The specific terms of each series, including interest structure and maturity, will be set in separate prospectus supplements.
The debt securities will be unsecured obligations issued under an existing indenture and may be sold directly or through agents, dealers, or underwriters. Unless a prospectus supplement states otherwise, net proceeds will be used for general corporate purposes such as working capital, capital expenditures, stock repurchase programs, refinancing of borrowings and acquisitions.
Johnson & Johnson files its annual report describing a diversified healthcare business built around two segments: Innovative Medicine and MedTech. Innovative Medicine spans oncology, immunology, neuroscience, infectious disease and cardiovascular care, with flagship drugs like DARZALEX, STELARA and TREMFYA contributing a significant share of revenue.
MedTech covers cardiovascular, orthopaedics, surgery and vision products, including electrophysiology tools, Shockwave and Abiomed technologies, surgical stapling and Acuvue contact lenses. The company plans to separate its Orthopaedics business within 18 to 24 months after an October 2025 announcement, adding execution and structural risk.
The report details extensive risk factors, including loss of patent exclusivity, biosimilar competition, global pricing pressure, U.S. Inflation Reduction Act drug price controls, complex regulation, large-scale litigation exposure, cybersecurity and data-privacy threats, global supply-chain vulnerabilities and geopolitical instability. J&J employs about 140,800 people worldwide and emphasizes human capital, culture, compliance and cybersecurity governance.
Johnson & Johnson executive Timothy Schmid, EVP and Worldwide Chair of MedTech, reported routine equity transactions on February 6, 2026. He exercised 15,571 employee stock options at $101.87 per share through an automatic exercise immediately before expiration, receiving the same number of common shares.
To cover the option exercise price and related taxes, 10,335 common shares were withheld at a value of $239.99 per share, leaving 22,125 common shares held directly after the transactions. He also reports indirect ownership of 745 shares through a 401(k) plan and 46 shares through an ESOP under the Johnson & Johnson Savings Plan.
Johnson & Johnson executive Kristen Mulholland, EVP and Chief HR Officer, reported routine equity activity involving stock options and common shares. On February 6, 2026, 5,625 employee stock options with a $101.87 exercise price were automatically exercised immediately before expiration, creating 5,625 shares of common stock.
To cover the option exercise price and related taxes, 3,335 common shares were withheld at a reference price of $239.99. After these transactions, Mulholland directly owned 16,409 shares of Johnson & Johnson common stock. The filing characterizes the option exercise as an automatic event tied to the option’s expiration.
Johnson & Johnson EVP and Chief TO and Risk Officer Kathryn E. Wengel reported an automatic exercise of employee stock options and related share withholding. On February 6, 2026, she exercised 38,945 employee stock options at $101.87 per share, receiving the same number of common shares.
To cover the option exercise price and taxes, 27,270 common shares were withheld at a value of $239.99 per share. After these transactions, she directly held 105,955.8735 Johnson & Johnson common shares, plus 281 shares held indirectly through an ESOP and 86 shares through a 401(k), both as of the plan reporting date.
Johnson & Johnson EVP and Chief Legal Officer Elizabeth Forminard reported an option exercise and related share sale. On 02/05/2026, she exercised employee stock options for 8,921 shares of common stock at $129.51 per share.
On the same date, 6,226 common shares coded "F" were sold in market trades at a weighted average price of $237.90, executed in multiple trades between $237.89 and $237.935. After these transactions, she directly held 15,548 shares of Johnson & Johnson common stock.